133 related articles for article (PubMed ID: 32706456)
1. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
Gill J; Zhang W; Zhang Z; Roth M; Harrison DJ; Rowshan S; Erickson S; Gatto G; Kurmasheva R; Houghton P; Teicher B; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Oct; 67(10):e28606. PubMed ID: 32706456
[TBL] [Abstract][Full Text] [Related]
2. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
[TBL] [Abstract][Full Text] [Related]
3. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
[TBL] [Abstract][Full Text] [Related]
4. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
[TBL] [Abstract][Full Text] [Related]
5. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
6. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Hingorani P; Collier A; Morris CD; Kolb EA; Doski JJ; Womer RB; Gorlick R; Janeway KA
Pediatr Blood Cancer; 2019 Feb; 66(2):e27524. PubMed ID: 30378256
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
[TBL] [Abstract][Full Text] [Related]
9. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.
Schott CR; Koehne AL; Sayles LC; Young EP; Luck C; Yu K; Lee AG; Breese MR; Leung SG; Xu H; Shah AT; Liu HY; Spillinger A; Behroozfard IH; Marini KD; Dinh PT; Pons Ventura MV; Vanderboon EN; Hazard FK; Cho SJ; Avedian RS; Mohler DG; Zimel M; Wustrack R; Curtis C; Sirota M; Sweet-Cordero EA
Clin Cancer Res; 2024 Feb; 30(4):849-864. PubMed ID: 37703185
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
Nakai S; Tamiya H; Imura Y; Nakai T; Yasuda N; Wakamatsu T; Tanaka T; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Yoshikawa H; Naka N
Mol Cancer Ther; 2020 Mar; 19(3):742-754. PubMed ID: 31796507
[TBL] [Abstract][Full Text] [Related]
13. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
[TBL] [Abstract][Full Text] [Related]
14. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma.
Reddy GB; Kerr DL; Spasojevic I; Tovmasyan A; Hsu DS; Brigman BE; Somarelli JA; Needham D; Eward WC
Mol Cancer Ther; 2020 Jul; 19(7):1448-1461. PubMed ID: 32371588
[TBL] [Abstract][Full Text] [Related]
16. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
17. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
[TBL] [Abstract][Full Text] [Related]
18. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Funahashi Y; Okamoto K; Adachi Y; Semba T; Uesugi M; Ozawa Y; Tohyama O; Uehara T; Kimura T; Watanabe H; Asano M; Kawano S; Tizon X; McCracken PJ; Matsui J; Aoshima K; Nomoto K; Oda Y
Cancer Sci; 2014 Oct; 105(10):1334-42. PubMed ID: 25060424
[TBL] [Abstract][Full Text] [Related]
20. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]